Cadent Therapeutics

Acquired

Cambridge, United States · Founded 2017 · $40.0M raised

Employees
11–50
Founded
2017
Business Model
B2B
Total Funding
$40.0M
Last Round
$40.0M Series BNov 2018
Rounds
1
Acquired by
Novartis AGJan 2021 · $770.0M

About

Cadent Therapeutics was a Cambridge, Massachusetts-based neuroscience company that developed novel therapies targeting NMDA receptors for neurological and psychiatric conditions, including schizophrenia, movement disorders, and treatment-resistant depression. The company was founded in early 2017 through a merger of Luc Therapeutics and Ataxion, and built a pipeline of clinical-stage assets including CAD-9303 (schizophrenia, Phase 1), CAD-1883 (movement disorders, Phase 2), and MIJ821 (treatment-resistant depression). Cadent was acquired by Novartis in a deal announced December 17, 2020 and closed in Q1 2021.

Summary

Cadent Therapeutics is a Biotech company based in Cambridge, United States, founded in 2017. It has raised $40.0M in total across 1 round, most recently a $40.0M Series B round in Nov 2018. Investors include Novartis Venture Fund, Cowen Healthcare Investments and Atlas Venture.

Funding History

AcquisitionJan 2021

Sign up to see all 2 rounds

Series B through Acquisition — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Cadent Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/cadent-therapeutics"><img src="https://indexed.vc/api/badge/company/cadent-therapeutics" alt="Cadent Therapeutics on Indexed.vc" width="260" height="76" /></a>